Erivedge (Vismodegib) is relevant in contexts involving advanced basal cell carcinoma (BCC), commonly used across conditions presenting with advanced or recurrent manifestations, addressing forms of the cancer that are either metastatic or locally advanced. It is indicated for these advanced manifestations, particularly when the disease has recurred following surgery, or where other local treatment modalities are not appropriate.

The therapy is commonly used across conditions presenting with advanced or recurrent manifestations, including metastatic basal cell carcinoma and locally advanced disease. It is applied across domains where additional symptomatic support is needed, addressing tumors that may cause significant discomfort or functional strain. Erivedge supports management of symptoms that interfere with daily functioning and assists with maintaining stability, providing relief for patients dealing with advanced cancer.

Quick Fact: Support for Advanced Cancer Symptoms

Eligibility for Erivedge (Vismodegib) Use

Official regulatory guidelines define strict population eligibility for Erivedge, which is approved only for adults 18 years and older. Its use is contraindicated in several specific populations due to the drug’s mechanism of action affecting the Hedgehog pathway, which is essential for development.

Populations Who Must Not Use Erivedge

Erivedge is strictly contraindicated in women who are pregnant or breastfeeding. Women of childbearing potential must comply with a stringent Pregnancy Prevention Programme and use effective contraception during and for 24 months after treatment. Use is not recommended in children and adolescents due to the serious risk of developmental toxicity, including premature fusion of bone growth plates.

Restrictions and Conditional Use

No specific dose adjustment is required for older adults (ge 65 years). However, the medicine is contraindicated if coadministered with the herbal product St. John's wort or in patients with specific rare hereditary enzyme deficiencies.

Interactions with other medicines and products

Vismodegib (Erivedge) interaction patterns are primarily pharmacokinetic, resulting from its role as a substrate for and inhibitor of specific enzymes and transporters, as described in regulatory documentation.

Contraindicated and Exposure-Altering Combinations

The co-administration of Vismodegib with strong CYP3A inducers is contraindicated. These substances, which include medicines like Rifampicin and the herbal supplement St. John's Wort, significantly decrease Vismodegib plasma concentrations (AUC and Cmax), potentially leading to a loss of clinical benefit.

Conversely, co-administration with strong CYP3A inhibitors, such as Ketoconazole or Clarithromycin, results in a significant increase in Vismodegib systemic exposure, requiring special consideration as outlined in official prescribing information.

Potential Interactions with Other Medicines

Official in vitro data indicates that Vismodegib acts as an inhibitor of the enzyme CYP2C9 and the efflux transporter P-glycoprotein (P-gp). This suggests a potential for Vismodegib to increase the plasma concentrations of co-administered medicines that are substrates for either CYP2C9 or P-gp.

Food and Population Notes

The presence of food does not cause a clinically significant effect on Vismodegib systemic exposure. For patients with mild or moderate hepatic impairment, a reduced clearance of Vismodegib is noted, which may impact the sensitivity to interactions with co-administered medicines.

Erivedge (Vismodegib) is a highly targeted molecule that operates through specific inhibition of a fundamental cell-signaling process. Its mechanism is strictly confined to the molecular and cellular level, affecting pathways that govern cellular expansion. The drug acts as an allosteric inhibitor by directly binding to the Smoothened (SMO) protein, a key transducer in the Hedgehog (Hh) signaling pathway. This binding stabilizes SMO in an inactive conformation, an initial molecular blockade that suppresses the signal required for cellular expansion. This inhibition prevents the release and activation of GLI transcription factors (GLI1, GLI2), which are the nuclear effectors. The resulting suppression of GLI-driven gene transcription leads to the core physiological change: the inhibition of cellular proliferation and survival in Hh pathway-dependent cells. The mechanism is limited by the development of pathway changes that bypass SMO inhibition, such as mutations that prevent drug binding (acquired mechanistic bypass) or downstream changes in GLI factors (intrinsic mechanistic bypass).

The administration of Erivedge (Vismodegib) is defined by a fixed, standardized usage protocol for systemic treatment. The medicine is supplied as a 150 mg hard capsule and is intended exclusively for oral use. The regimen is strictly once daily, and the prescribed dose of 150 mg is fixed and not typically subject to adjustment when beginning therapy in adults.

Administration Instructions

The protocol for taking the capsule is established to ensure proper use. The capsule must be swallowed whole and must not be opened or crushed. This daily dose may be taken with or without food.

Duration and Specific Use Rules

Erivedge is typically administered as a continuous treatment. Use is maintained until clinical criteria are met, such as evidence of disease progression or the onset of unacceptable adverse reactions. If a dose is missed, it must not be taken later in the day, and the patient should simply resume the regular schedule at the next scheduled time. No dose adjustment is generally required for older adults (65 years) or for patients with mild to moderate kidney or liver impairment. The medicine is not intended for use in the pediatric population.

Research Evidence for Locally Advanced Basal Cell Carcinoma (laBCC)

Research has explored the use of vismodegib in adult patients with locally advanced basal cell carcinoma (laBCC). This medicine was studied for use in laBCC, particularly in cases where standard local treatments, such as surgery or radiation, were not appropriate or had been unsuccessful. The initial core evidence includes a pivotal Phase II clinical trial, which utilized a single-arm design, meaning it did not include a control or comparison group. This trial was evaluated in patients where local treatment options had been utilized.

In these studies, researchers monitored several outcomes related to tumor status and disease progression. Primary goals included measuring the Objective Response Rate (ORR), which tracked changes in tumor size, ulceration, and biopsy results, as well as the Duration of Response (DOR). Findings describe patterns observed in the studies, where ORR measurements were reported across the observed populations over a primary assessment period of approximately six months.

Research Evidence for Metastatic Basal Cell Carcinoma (mBCC)

Vismodegib was studied in a specific, smaller patient cohort within the pivotal Phase II trial for individuals diagnosed with metastatic basal cell carcinoma (mBCC). This condition is relatively rare. Research examined radiographic outcomes and overall disease progression. The researchers used standard radiographic criteria, known as RECIST, to measure the Objective Response Rate (ORR) in patients whose condition had spread to distant sites.

The findings highlight changes measured during the study period, primarily focused on the short-term outcomes related to disease status. Studies reported the rates of objective change in the observed populations, and the collected evidence contributes to understanding disease response patterns in this rare condition.

Key Limitations and Areas of Research Uncertainty

Research highlights what is known—and what is still uncertain. The research base includes study design limitations, as the primary studies utilized single-arm designs, meaning comparative evidence against a placebo or another treatment was not included within that foundational data set. Additionally, sample sizes were modest, particularly for the rare metastatic form of the condition.

Long-term effects are not well characterized, as follow-up durations were limited. Furthermore, the high rate of treatment discontinuation observed in larger studies means that data on the continuous use and long-term status of the condition remain limited. The evidence contributes to the broader evidence landscape but requires ongoing research to fill these gaps.

Common questions about Erivedge (FAQ)

Q: What kind of Basal Cell Carcinoma is Erivedge prescribed for?

A: Official documents state that Erivedge is indicated for adults with advanced forms of Basal Cell Carcinoma (BCC). This includes metastatic BCC (mBCC), which has spread to other parts of the body, or locally advanced BCC (laBCC) when it has recurred after surgery, or if surgery and radiation treatments are not considered appropriate options.

Q: How long after starting Erivedge might a patient notice a change?

A: In clinical studies, researchers tracked changes in tumor status using a measure called the objective response rate (ORR). Findings indicate that this initial response was typically assessed over a primary period of approximately six months from the start of treatment. The six-month period represents the time frame over which initial changes were measured in the clinical study population.

Q: How long does Erivedge stay in the system after the last dose?

A: Erivedge has a long half-life, meaning it remains in the body for an extended time after treatment is stopped. Due to the risk of severe harm to a developing fetus, official safety programs describe the need for women to use effective contraception for 24 months and for men to use barrier contraception for 3 months following the final dose.

Q: How does Erivedge differ from other common skin cancer treatments?

A: Official product information describes Erivedge as a targeted therapy and a Hedgehog pathway inhibitor, which is a systemic treatment. This distinguishes it from local treatments such as surgery or radiation, which treat a specific area. Erivedge is designed to act on a specific cellular signaling process in the body.

Q: Can men using Erivedge still father children?

A: Official safety programs address this question through strict measures. The medicine is known to be present in semen and carries a risk of severe birth defects if transferred during conception. Because of this risk, official safety programs describe the need for male patients of reproductive potential to use a condom during treatment and for 3 months after the final dose to help prevent exposure to a female partner.

Q: What should a patient know about sun exposure while taking Erivedge?

A: Official prescribing information does not list sun sensitivity (photosensitivity) as a common or serious adverse reaction. However, the most common side effect is hair loss (alopecia). Since hair loss is very common, general guidance in patient materials often includes protecting the scalp and skin from sun exposure.

Q: What are the most common side effects people talk about with Erivedge?

A: Regulatory documents list the most frequently reported adverse reactions, which occurred in at least 10% of patients during clinical trials. These very common side effects include muscle spasms, hair loss (alopecia), altered or lost sense of taste (dysgeusia/ageusia), weight loss, fatigue, nausea, and diarrhea.

Q: Does Erivedge cause hair loss, and is it permanent?

A: Hair loss (alopecia) is listed in official documentation as a Very Common side effect, meaning it occurred in more than 10% of patients in clinical trials. However, regulatory labels do not specify whether this hair loss is permanent or reversible for all patients.

Q: Are there any foods or supplements that should be avoided with Erivedge?

A: Official information explicitly contraindicates co-administration with the herbal supplement St. John's Wort, as it can reduce the medicine’s effectiveness. The capsule can otherwise be taken with or without food, as eating does not significantly impact how the medicine is absorbed.

Q: Does taking Erivedge affect the ability to drive or operate machinery?

A: According to official documents, the effect of Erivedge on a patient's ability to drive and use machines is not expected to be relevant. If side effects such as fatigue are experienced, it is important for the patient to communicate this with their healthcare provider.

Q: What happens if Erivedge treatment needs to be stopped suddenly?

A: Treatment is typically maintained until the disease progresses or side effects become unacceptable. Official documents note that discontinuation may be required by a healthcare provider due to disease progression or unacceptable toxicity. They do not contain specific warnings against immediate discontinuation when medically supervised.

Q: Can Erivedge interact with common blood pressure medications?

A: Official labels indicate that Erivedge can affect the enzymes and transporters that process other drugs in the body, such as the CYP2C9 enzyme. This means it has the potential to increase the plasma concentration of other medicines that are processed this way, which could include some blood pressure medications. Information about all co-administered medicines is important for a healthcare provider to review.

Q: What specific type of specialist usually prescribes Erivedge?

A: Official guidelines state that Erivedge should only be prescribed by, or under the close supervision of, a specialist physician experienced in the management of the approved indication (advanced basal cell carcinoma). This is to ensure patients receive appropriate monitoring and management.

Q: How often are blood tests required when a person is taking Erivedge?

A: The frequency of general monitoring blood tests can vary. However, official safety protocols require that female patients of childbearing potential undergo a negative pregnancy test monthly throughout the duration of treatment. Monitoring may also be done for certain lab values, such as CPK elevations or electrolyte imbalances.

Q: Is there any research evidence on Erivedge effectiveness in older adults?

A: Official information confirms that no specific dose adjustment is required for patients 65 years of age or older. However, official regulatory documents do not provide separate data summaries or conclusions specifically on efficacy for older adults compared to the overall study population.

Q: Can Erivedge be taken with antacids or heartburn medicines?

A: A clinical study was conducted examining the co-administration of Vismodegib with a proton pump inhibitor (a common type of heartburn medicine). The interaction was found to be not expected to be clinically significant, which indicates that co-administration with a proton pump inhibitor did not substantially alter the drug's exposure.

Q: Does Erivedge have a Boxed Warning, and what is it about?

A: Yes, Erivedge has a Boxed Warning (also known as a Black Box Warning) as mandated by the FDA. This is the strongest type of warning for a medicine. The warning is specifically regarding Embryo-Fetal Toxicity, indicating the medicine can cause death or severe, irreversible birth defects when used during pregnancy.

Q: What percentage of patients in studies experienced specific side effects?

A: Official product information uses specific tables to detail the percentage of patients who experienced the most frequent adverse reactions in clinical trials. For example, the rate of muscle spasms was 71% and hair loss (alopecia) was 64% in the initial pivotal study.

Q: Are there known interactions with common antibiotics?

A: Official documents warn about interactions with medicines classified as strong CYP3A inhibitors and P-glycoprotein inhibitors. This class includes certain antibiotics, such as clarithromycin and erythromycin, which could potentially increase the amount of Erivedge in the bloodstream.

Storage and Disposal Requirements for Erivedge

Erivedge (vismodegib) capsules require adherence to specific storage and handling rules as mandated by regulatory documents to ensure stability and safety.

Storage Conditions

Erivedge must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F). The product must be kept in its original container, which should be tightly closed to protect the medicine from both moisture and light. It is explicitly required that Erivedge be kept from freezing and stored out of the reach of children.

Handling and Disposal

Capsules must be swallowed whole and must not be opened, crushed, or chewed to prevent exposure. For disposal, unused or expired capsules must not be thrown in household trash or flushed down the toilet or sink. The official procedure requires consulting a pharmacist or healthcare provider for proper disposal.